A novel cellobiose-polylysine dendrimer with reducing sugar terminals was synthesized in which the reactive reducing end of a disaccharide cellobiose was directing outward. Hexa-O-benzyl-4Ј-(1-carboxyethyl)-cellobioside (HBCEC) was synthesized through the reaction of a 4Ј-hydroxyl group of benzyl hexa-O-benzyl-cellobioside with methyl 2-chloropropionate, followed by the removal of the methyl ester group. HBCEC was reacted with polylysine dendrimer generation 3 (G3) to produce benzylated cellobiose-polylysine dendrimer G3. After debenzylation, a cellobiose-polylysine dendrimer G3 was obtained in which the reducing end of the cellobiose was the terminal group of the dendrimer. For the preparation of a dendrimer-type acquired immunodeficiency syndrome vaccine, the cellobiose-polylysine dendrimer was reacted with a tripeptide (glycyl-prolyl-leucine) and a cyclic oligopeptide from the human immunodeficiency virus by reductive amination; this produced a tripeptide-bound cellobiose-polylysine dendrimer and an insoluble compound, respectively. The structure analysis was carried out with NMR and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. 13 (36 mg, 8.7 mol) and Gly-Pro-Leu (20 mg, 70 mol) were dissolved in a 0.1 M borate buffer (pH 9.0, 5 mL). After BH 3 /pyridine (80 mL, 800 mmol) was added, the solution was stirred at 37°C for 5 days. The resulting compound was purified by dialysis and then freeze-dried from water to produce Gly-Pro-Leu-cellobiose-polylysine dendrimer G3 (14; 32 mg) as a white powder.
Preparation of Cyclic V3 Loop-Cellobiose-Polylysine Dendrimer G3The cyclic V3 loop (10 mg, 3 mmol) was suspended in 5 mL of a 0.1 M borate buffer (pH 9.0). After cellobiose-polylysine dendrimer (12 mg, 3 mmol) and BH 3 /pyridine (12 mL, 118 mmol) were added, the suspension was stirred at 37°C for 5 days.
OLIGOSACCHARIDE-POLYLYSINE DENDRIMER